Anticancer properties of complexes derived from bidentate ligands

Cancer is the abnormal division and multiplication of cells in an organ or tissue. It is the second leading cause of death globally. There are various types of cancer such as prostate, breast, colon, lung, stomach, liver, skin, and many others depending on the tissue or organ where the abnormal growth originates. Despite the huge investment in the development of anticancer agents, the transition of research to medications that improve substantially the treatment of cancer is less than 10%. Cisplatin and its analogs are ubiquitous metal-based anticancer agents notable for the treatment of various cancerous cells and tumors but unfortunately accompanied by large toxicities due to low selectivity between cancerous and normal cells. The improved toxicity profile of cisplatin analogs bearing bidentate ligands has motivated the synthesis of vast metal complexes of bidentate ligands. Complexes derived from bidentate ligands such as β-diketones, diolefins, benzimidazoles and dithiocarbamates have been reported to possess 20 to 15,600-fold better anticancer activity, when tested on cell lines, than some known antitumor drugs currently on the market, e.g. cisplatin, oxaliplatin, carboplatin, doxorubicin, and 5-fluorouracil. This work discusses the anticancer properties of various metal complexes derived from bidentate ligands, for possible application in chemotherapy. The results discussed were evaluated by the IC50 values as obtained from cell line tests on various metal-bidentate complexes. The structure-activity relationship study of the complexes discussed, revealed that hydrophobicity is a key factor that influences anticancer properties of molecules.

Luminescent Heterobimetallic PtII-AuI Complexes Bearing N-Heterocyclic Carbenes (NHCs) as Potent Anticancer Agents

This study aims to probe into new series of heterobimetallic PtII-AuI complexes with a general formula of [Pt(p-MeC6H4)(dfppy)(μ-dppm)Au(NHC)]OTf, NHC = IPr, 2; IMes, 3; dfppy = 2-(2,4-difluorophenyl)pyridinate; dppm = 1,1-bis(diphenylphosphino)methane, which are the resultant of the reaction between [Pt(p-MeC6H4)(dfppy)(κ1-dppm)], 1, with [AuCl(NHC)], NHC = IPr, B; IMes, C, in the presence of [Ag(OTf)]. In the heterobimetallic complexes, the dppm ligand is settled between both metals as an unsymmetrical bridging ligand. Several techniques are employed to characterize the resulting compounds. Moreover, the photophysical properties of the complexes are investigated by means of UV-vis and photoluminescence spectroscopy. Furthermore, the experimental study is enriched by ab initio calculations (density functional theory (DFT) and time-dependent DFT (TD-DFT)) to assess the role of Pt and Au moieties in the observed optical properties. It is revealed that 1-3 is luminescent in the solid state and solution at different temperatures. In addition, the achieved results indicate the emissive properties of 1-3 are originated from a mixed 3IL/3MLCT excited state with major contribution of intraligand charge transfer (dfppy). A comparative study is conducted into the cytotoxic activities of starting materials and 1-3 against different human cancer cell lines such as the pancreas (MIA-PaCa2), breast (MDA-MB-231), cervix (HeLa), and noncancerous breast epithelial cell line (MCF-10A). The achieved results suggest the heterobimetallic PtII-AuI species as optimal compounds that signify the existence of cooperative and synergistic effects in their structures. The complex 3 is considered as the most cytotoxic compound with the maximum selectivity index in our screened complex series. Moreover, it is disclosed that 3 effectively causes cell death by inducing apoptosis in MIA-PaCa2 cells. Furthermore, the finding results by fluorescent cell microscopy manifest cytoplasmic staining of 3 rather than nucleus.

Oral Anticancer Heterobimetallic PtIV -AuI Complexes Show High In Vivo Activity and Low Toxicity

Au^I -carbene and Pt^IV -Au^I -carbene prodrugs display low to sub-μM activity against several cancer cell lines and overcome cisplatin (cisPt) resistance. Linking a cisPt-derived Pt^IV (phenylbutyrate) complex to a Au^I -phenylimidazolylidene complex 2, yielded the most potent prodrug. While in vivo tests against Lewis Lung Carcinoma showed that the prodrug Pt^IV (phenylbutyrate)-Au^I -carbene (7) and the 1 : 1 : 1 co-administration of cisPt: phenylbutyrate:2 efficiently inhibited tumor growth (≈95 %), much better than 2 (75 %) or cisPt (84 %), 7 exhibited only 5 % body weight loss compared to 14 % for 2, 20 % for cisPt and >30 % for the co-administration. 7 was much more efficient than 2 at inhibiting TrxR activity in the isolated enzyme, in cells and in the tumor, even though it was much less efficient than 2 at binding to selenocysteine peptides modeling the active site of TrxR. Organ distribution and laser-ablation (LA)-ICP-TOFMS imaging suggest that 7 arrives intact at the tumor and is activated there.

Promising heterometallic compounds as anticancer agents: Recent studies in vivo

Over the past decade, interest on multitarget anticancer drugs -including heterometallic compounds-has increased considerably. Heterometallic species display improved efficacy and physicochemical properties compared to the individual metallic fragments for a variety of metal pair combinations. By 2018, several compounds had emerged as promising candidates against cisplatin resistant cancers. Here, we summarize research contributions to this topic over the past four years (July 2018-July 2022). In particular, we highlight five articles reporting on the in vivo activity and preliminary mechanisms of action for five groups of compounds. From this selection, we further feature two families of compounds based on Pt(IV)-Gd(III) and Ti(IV)-Au(I) metal combinations, given their potential for clinical translation.

Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments

Although important progress has been made, cancer still remains a complex disease to treat. Serious side effects, the insurgence of resistance and poor selectivity are some of the problems associated with the classical metal-based anti-cancer therapies currently in clinical use. New treatment approaches are still needed to increase cancer patient survival without cancer recurrence. Herein, we reviewed two promising-at least in our opinion-new strategies to increase the efficacy of transition metal-based complexes. First, we considered the possibility of assembling two biologically active fragments containing different metal centres into the same molecule, thus obtaining a heterobimetallic complex. A critical comparison with the monometallic counterparts was done. The reviewed literature has been divided into two groups: the case of platinum; the case of gold. Secondly, the conjugation of metal-based complexes to a targeting moiety was discussed. Particularly, we highlighted some interesting examples of compounds targeting cancer cell organelles according to a third-order targeting approach, and complexes targeting the whole cancer cell, according to a second-order targeting strategy.

Antiproliferative activity and DNA binding studies of cyclometalated complexes of platinum(II) containing 2-vinylpyridine

The cytotoxic activity of four cyclometalated platinum(II) complexes [PtMe(vpy)(L)], containing 2-vinylpyridine (vpy) and the phosphine ligands (L) PMe₂Ph (1a), PPh₃ (1b), PMePh₂ (1c), and P(c-Hex)₃ (1d), were evaluated against human breast cancer (MDA-MB-231), human lung cancer (A549), human colon cancer (SW1116), and non-tumor epithelial breast (MCF-10 A) cell lines. The highest activity was found for 1c with IC₅₀ values of 21.10 µM, 23.36 µM, and 12.96 µM, compared to cisplatin, which was 10.12 µM, 47.57 µM, and 19.50 µM against the A549, SW1116, and MDA-MB-231 cell lines, respectively. 1a-d showed a higher selectivity index (SI) than cisplatin. Docking studies confirmed interaction to the DNA minor groove for all complexes. Genotoxicity studies on 1c showed interactions with the genomic content of malignant cells. Compared with cisplatin as a positive control, a slight shift was found in the electrophoresis mobility, which was utilized further to study the direct interaction of 1c with DNA.

Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives

Platinum-based anticancer drugs are among the most widely used antineoplastics in clinical settings. Their therapeutic applications and outcomes are, however, greatly hampered by drug resistance, systemic toxicity, and the lack...

Homo and heterobimetallic palladium and platinum complexes bearing μ-diphosphane bridges involved in biological studies

Given the increasing reports of well-defined bimetallic molecular complexes as potential anticancer agents in the last decades, along with the prevalence of platinum in anticancer therapy, we report here a detailed survey of bimetallic platinum and palladium complexes investigated as potential anticancer agents. Specifically, we will concentrate on the synthesis, characterisation and biological (anticancer) studies of a sub-class of these agents, namely homo and heterobimetallic complexes bearing a bridging phosphane ligand of the type: [L_nM₁(μ-R₂P(CH₂)_nPR₂)M₂L_m] (where M₁ is platinum or palladium, M₂ is any other transition metal, R = alkyl or aryl substituents, L_n or L_m are co-ligands, n = 1-6). We will review the in vitro and in vivo activities and any mechanistic anticancer studies of these complexes with a view of trying to delineate patterns in biological activity and structure-activity relationships (SAR). We do not include the review of bimetallic complexes in this class that have not undergone any anticancer testing, nor those that have been involved in other biological investigations unrelated to cancer studies.

Photophysical Properties and Kinetic Studies of 2-Vinylpyridine-Based Cycloplatinated(II) Complexes Containing Various Phosphine Ligands

A series of cycloplatinated(II) complexes with general formula of [PtMe(Vpy)(PR₃)], Vpy = 2-vinylpyridine and PR₃ = PPh₃ (1a); PPh₂Me (1b); PPhMe₂ (1c), were synthesized and characterized by means of spectroscopic methods. These cycloplatinated(II) complexes were luminescent at room temperature in the yellow–orange region’s structured bands. The PPhMe₂ derivative was the strongest emissive among the complexes, and the complex with PPh₃ was the weakest one. Similar to many luminescent cycloplatinated(II) complexes, the emission was mainly localized on the Vpy cyclometalated ligand as the main chromophoric moiety. The present cycloplatinated(II) complexes were oxidatively reacted with MeI to yield the corresponding cycloplatinated(IV) complexes. The kinetic studies of the reaction point out to an S_N2 mechanism. The complex with PPhMe₂ ligand exhibited the fastest oxidative addition reaction due to the most electron-rich Pt(II) center in its structure, whereas the PPh₃ derivative showed the slowest one. Interestingly, for the PPhMe₂ analog, the trans isomer was stable and could be isolated as both kinetic and thermodynamic product, while the other two underwent trans to cis isomerization.

Heterobimetallic platinum(ii) complexes with increased cytotoxicity against ovarian cancer cell lines

Two series of heterobimetallic compounds were prepared from the starting complex [cis-L2PtCl2] containing an aminophosphine ligand (L = 2,6-iPr2-C6H3-NHPPh2).

A C^N Cycloplatinated(II) Fluoride Complex: Photophysical Studies and Csp3-F Bond Formation

This work reports the synthesis and characterization of a new C^N-based cycloplatinated(II) fluoride complex, [Pt(ppy)(PPh₃)F] (2; ppy = 2-phenylpyridinate), involving a Pt-F bond. The new complex is highly luminescent in the green area with a high quantum yield of 94.6% at 77 K. A comparison study of the heavier halogen derivatives reveals a descending emission quantum yield order of F > Cl > Br > I. Time-dependent density functional theory calculations ascribe the decreased emission efficiency to the decreasing trend of an intraligand (IL) transition from F to I, which accounts for the major radiative pathway. In addition, 2 is capable of the fluorinating alkyl halides, leading to C_sp³-F bond formation at room temperature.

A review on 1,1-bis(diphenylphosphino)methane bridged homo- and heterobimetallic complexes for anticancer applications: Synthesis, structure, and cytotoxicity

Herein, we review developments in synthesis, structure, and biological (anti-cancer) activities of 1,1-bis(diphenylphosphino)methane (dppm) bridged homo- and heterobimetallic systems of the type L_mM(μ₂-dppm)M'L_n (M and M' are transition metals which may be different or the same and L_n,m are co-ligands) since the first such reported bimetallic system in 1987 until the present time (2020). As the simplest diphosphine, dppm enables facile formation of bimetallic complexes, where, given the short spacer between the PPh₂ groups, close spatial proximity of the metal centres is ensured. We concentrate on complexes bearing no M-M interaction and contrast biological activities of these complexes with mononuclear counterparts and positive control agents such as cisplatin, in an attempt to elucidate patterns in the biological activities of these complexes.

Design, synthesis, molecular simulation, and biological activities of novel quinazolinone-pyrimidine hybrid derivatives as dipeptidyl peptidase-4 inhibitors and anticancer agents

Twelve novel quinazolinone–pyrimidine hybrids were synthesized, of which some of them showed dual functions as DPP-4 inhibitors and anti-cancer agents.